Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 After Once Daily Administration of Multiple Ascending Doses for 10 Days, and an Open-label Comparison With the Pharmacodynamics of AZD5069 Given Twice Daily for 3 Days

Trial Profile

A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 After Once Daily Administration of Multiple Ascending Doses for 10 Days, and an Open-label Comparison With the Pharmacodynamics of AZD5069 Given Twice Daily for 3 Days

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 4721 (Primary) ; AZD 5069 (Primary)
  • Indications Asthma; Bronchiectasis; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014, as per ClinicalTrials.gov record.
    • 27 Nov 2013 Planned number of patients changed from 60 to 57 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top